| Literature DB >> 33915701 |
Carlo Tomino1, Sara Ilari2, Vincenzo Solfrizzi3, Valentina Malafoglia4, Guglielmo Zilio5, Patrizia Russo6,7, Stefania Proietti1, Federica Marcolongo6, Giovanni Scapagnini8, Carolina Muscoli2, Paolo Maria Rossini9.
Abstract
Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761® for the treatment of dementia syndromes and EGb 761® combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761® in mixed therapy.Entities:
Keywords: Alzheimer’s disease; Ginkgo biloba (Egb761®); Tebonin; anti-dementia drugs; mild cognitive impairment (MCI); mild dementia; randomized controlled trials
Year: 2021 PMID: 33915701 DOI: 10.3390/ph14040305
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247